The main purpose of this study is to determine whether treatment with the SGLT2 inhibitor luseogliflozin affects bone metabolism in older patients with T2DM by using second-generation HR-pQCT. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.